Jump to content

Iproclozide

From Wikipedia, the free encyclopedia
Iproclozide
Clinical data
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • BR: Class C1 (Other controlled substances)[1]
  • In general: uncontrolled
Identifiers
  • 2-(4-chlorophenoxy)-N-isopropyl-acetohydrazide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.020.536 Edit this at Wikidata
Chemical and physical data
FormulaC11H15ClN2O2
Molar mass242.70 g·mol−1
3D model (JSmol)
  • Clc1ccc(OCC(=O)NNC(C)C)cc1
  • InChI=1S/C11H15ClN2O2/c1-8(2)13-14-11(15)7-16-10-5-3-9(12)4-6-10/h3-6,8,13H,7H2,1-2H3,(H,14,15) checkY
  • Key:GGECDTUJZOXAAR-UHFFFAOYSA-N checkY
  (verify)

Iproclozide (trade names Sursum, Sinderesin) is an irreversible and selective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant, but has since been discontinued.[2] It has been known to cause fulminant hepatitis and there have been at least three reported fatalities due to administration of the drug.[3][4]

See also

[edit]

References

[edit]
  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ Suerinck A, Suerinck E (April 1966). "[Depressive states in a sanatorium milieu and monoamine oxidase inhibitors. (Therapeutic results by the combination of iproclozide and chlordiazepoxide). Apropos of 146 cases]". Journal de Médecine de Lyon. 47 (96): 573–586. PMID 5930723.
  3. ^ Pessayre D, de Saint-Louvent P, Degott C, Bernuau J, Rueff B, Benhamou JP (September 1978). "Iproclozide fulminant hepatitis. Possible role of enzyme induction". Gastroenterology. 75 (3): 492–496. doi:10.1016/0016-5085(78)90856-9. PMID 680506.
  4. ^ Kaplowitz N, DeLeve LD (2003). Drug-induced liver disease. Informa Health Care. p. 455. ISBN 0-8247-0811-3.